Spirulina.Guru

Science

Spirulina and primary sclerosing cholangitis.

Primary sclerosing cholangitis (PSC) is a progressive cholestatic liver disease characterised by multifocal biliary stricturing and fibrosis, eventual cirrhosis, and a markedly elevated risk of cholangiocarcinoma (lifetime risk ~15%). Unlike PBC, no proven medical therapy alters its natural history. The management challenges of PSC — IBD co-management, nutritional deficiencies, pruritus, and malignancy surveillance — create a complex backdrop for spirulina supplementation.

PSC pathophysiology

  • Periductal fibrosis mechanism: PSC involves progressive concentric periductal fibrosis (“onion-skin” pattern on biopsy) of both intra- and extrahepatic bile ducts. The aetiology involves gut-liver axis dysfunction: intestinal dysbiosis and increased gut permeability allow microbial products (bacterial PAMPs) to reach the biliary epithelium via the portal circulation. Biliary epithelial TLR4 activation drives NF-κB/NOX2 inflammation and cholangiocyte senescence.
  • IBD overlap: 70–80% of PSC patients have IBD, almost exclusively ulcerative colitis (not Crohn’s). PSC-IBD is a distinct phenotype: right-sided pan-colitis, backwash ileitis, low disease activity despite PSC severity, high colorectal cancer risk. When considering spirulina in PSC-IBD: assess both the PSC NK concern and the UC disease activity status separately.
  • NK and T cell biliary infiltrate: As in PBC, NK cells and CD8+ T cells are present in the biliary infiltrate in PSC. NK stimulation concern is intermediate to high in PSC. Discuss with hepatologist before starting spirulina in PSC.

Cholangiocarcinoma risk

  • PSC carries a lifetime cholangiocarcinoma (CCA) risk of approximately 10–20%. This is not modified by spirulina supplementation. PSC patients should undergo regular CCA surveillance (MRI cholangiography, CA 19-9 monitoring) as directed by their hepatologist. Any new jaundice, right upper quadrant pain, weight loss, or rising CA 19-9 requires urgent assessment. Spirulina has no role in CCA prevention or surveillance.

Fat-soluble vitamins and cholestasis

  • In advanced PSC with significant cholestasis, fat-soluble vitamin (A, D, E, K) absorption is impaired. Spirulina beta-carotene (pro-vitamin A) and vitamin K have reduced bioavailability in severe cholestasis for the same reasons as in PBC. Water-miscible fat-soluble vitamin preparations are preferred in advanced PSC. Warfarin interaction (vitamin K): consistent daily spirulina dosing essential if on warfarin (portal hypertension complications may necessitate anticoagulation).

Drug interactions

UDCA (controversial in PSC)

  • UDCA reduces serum liver enzymes in PSC but did not improve survival in the high-dose UDCA trial (28–30 mg/kg/day increased serious adverse events in some studies). Current EASL guidelines do not recommend UDCA for PSC outside of clinical trials; some centres use low-dose UDCA (13–15 mg/kg/day) for symptom management. No pharmacokinetic interaction with spirulina; separate from UDCA by at least 1 hour.

Cholestyramine (pruritus)

  • Cholestyramine is a bile acid sequestrant used for cholestatic pruritus. It binds bile acids (and other compounds) in the GI lumen. IMPORTANT: cholestyramine binds spirulina components and other supplements and medications in the GI lumen, reducing their absorption. Take spirulina at least 2 hours before or 4–6 hours after cholestyramine. Do not take spirulina at the same time as cholestyramine.

Vancomycin (paediatric PSC)

  • Oral vancomycin is used in some paediatric and adult PSC centres (primarily paediatric) as an experimental treatment modifying gut microbiota. No pharmacokinetic interaction with spirulina at the oral route (vancomycin is not absorbed from the GI tract; systemic exposure is negligible with oral administration).

Rifaximin (gut microbiota)

  • Rifaximin is sometimes used experimentally in PSC for gut microbiome modulation. No pharmacokinetic interaction with spirulina. Rifaximin and spirulina prebiotic polysaccharides both modulate gut microbiota via different mechanisms (antibiotic vs prebiotic substrate); no pharmacological conflict.

Practical guidance

  • PSC: intermediate to high NK concern (biliary NK cell infiltrate); discuss with hepatologist before starting spirulina
  • If approved: start 1 g/day; recheck LFTs 6–8 weeks after starting; increase to 3–5 g/day if no biochemical change
  • CRITICAL: CoA-verified product only (microcystins <1 µg/g); hepatotoxic spirulina contamination in an already-damaged biliary system is particularly harmful
  • Cholestyramine: take spirulina ≥2 hours before or 4–6 hours after; do not co-administer
  • Advanced cholestasis: water-miscible fat-soluble vitamins preferred over spirulina for specific deficiency management
  • PSC-IBD: assess UC disease activity separately; stable UC on mesalazine is lower concern than active UC on biologics

Related reading

Get the weekly digest

Curated science, recipes, and brand intel — once a week, no spam, unsubscribe in one click.